Back

Predictors of lipid-lowering therapy intensification over 1 year of prospective follow-up in Europe: insights from the SANTORINI study

29 August 2025 (09:40 - 09:50)
Organised by: Logo
Congress Presentation Part of: Changing face of lipid-lowering therapy Drug therapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Carlos Aguiar

Hospital Santa Cruz, Lisbon (Portugal)

5 More presentations in this session

Presentation thumbnail
Temporal trends in lipid-lowering therapy utilization among ASCVD patients: a large-scale database analysis
Doctor M. Goldberg (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
Real-world prescribing patterns for lipid-lowering therapy in high cardiovascular risk patients in germany: a cross-sectional analysis
Professor O. Weingaertner (Jena, DE)
Abstract Slides Video
Presentation thumbnail
Oral PCSK9 inhibitors as an emerging frontier in lipid management: a meta-analysis
Mr V. Ho (Debrecen, HU)
Abstract Slides Video
Presentation thumbnail
Efficacy of obicetrapib across the spectrum of background lipid lowering therapies-pooled analyses of the Broadway and Brooklyn randomised trials
Professor K. Ray (London, GB)
Abstract Slides Video
Presentation thumbnail
Statin adherence in primary care among patients with hypertension with and without other cardiometabolic diseases
Doctor J. Sandslatt (Gothenburg, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Changing face of lipid-lowering therapy
Video

The Event

Event poster

ESC Congress 2025

29 August 2025 09:40 CET
You may be interested in
thumbnail
Congress Session
Changing face of lipid-lowering therapy
thumbnail
Congress Presentation
Triple oral lipid-lowering treatment pathway and associated outcomes in high- and very high-cv risk patients: a simulation using the SANTORINI study cohort
thumbnail
Congress Session
Registries, observational, and other studies on lipids

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources